{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:12:02Z","timestamp":1777885922857,"version":"3.51.4"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2016283"],"award-info":[{"award-number":["GNT2016283"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105228","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T16:14:37Z","timestamp":1771690477000},"page":"105228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond initial response: Acquired resistance to hypomethylating agents in myeloid malignancies"],"prefix":"10.1016","volume":"221","author":[{"given":"Brooke M.","family":"Harvey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anoop K.","family":"Enjeti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle R.","family":"Bond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6482-0337","authenticated-orcid":false,"given":"Heather J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-58689-1","article-title":"SMS121, a new inhibitor of CD36, impairs fatty acid uptake and viability of acute myeloid leukemia","volume":"14","author":"\u00c5backa","year":"2024","journal-title":"Sci. Rep."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105228_bib2","article-title":"Effect of hypomethylating agent (HMA) exposure on survival of secondary acute myeloid leukemia (sAML) from myelodysplastic syndrome (MDS)","volume":"41","author":"Adrianzen Herrera","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105228_bib3","unstructured":"AIHW (Australian Institute of Health and Welfare), 2021 Australian Cancer Incidence and Mortality (ACIM) books: Acute myeloid leukaemia, 2021."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01054-2","article-title":"RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives","volume":"14","author":"Alawieh","year":"2024","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib5","article-title":"Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood","volume":"14","author":"Badar","year":"2024","journal-title":"Cancer J."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105228_bib6","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","article-title":"Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure","volume":"4","author":"Ball","year":"2020","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105228_bib7","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.chembiol.2012.03.010","article-title":"Specificity of Dnmt1 for Methylation of Hemimethylated CpG Sites Resides in Its Catalytic Domain","volume":"19","author":"Bashtrykov","year":"2012","journal-title":"Chem. Biol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105228_bib8","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1038\/s41375-025-02693-5","article-title":"Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal","volume":"39","author":"Bond","year":"2025","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01076-4","article-title":"Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine","volume":"14","author":"Buettner","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105228_bib10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/2767-9764.CRC-23-0389","article-title":"Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy","volume":"4","author":"Campillo-Marcos","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/16078454.2021.1889161","article-title":"Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes","volume":"26","author":"Cheng","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.critrevonc.2026.105228_bib12","first-page":"2548","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01657-z","article-title":"Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1\/2 trial","volume":"18","author":"Cortes","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105228_bib14","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/leu.2012.312","article-title":"Azacitidine fails to eradicate leukemic stem\/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia","volume":"27","author":"Craddock","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105228_bib15","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41375-018-0070-8","article-title":"Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes","volume":"32","author":"Daver","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105228_bib16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105228_bib17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105228_bib18","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105228_bib19","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2022008378","article-title":"Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2 -mutant myelodysplastic syndrome","volume":"7","author":"DiNardo","year":"2023","journal-title":"Blood Adv."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105228_bib20","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105228_bib21","series-title":"Myelodysplastic Syndrome","article-title":"Treasure Island (FL)","author":"Dotson","year":"2025"},{"key":"10.1016\/j.critrevonc.2026.105228_bib22","unstructured":"EMA (European Medicines Agency), Vidaza - Product Information Sheet, 2008."},{"key":"10.1016\/j.critrevonc.2026.105228_bib23","unstructured":"EMA (European Medicines Agency), Dacogen - Product Information Sheet, 2012."},{"key":"10.1016\/j.critrevonc.2026.105228_bib24","unstructured":"EMA (European Medicines Agency), Venclyxto - Product Information Sheet, 2016."},{"key":"10.1016\/j.critrevonc.2026.105228_bib25","unstructured":"EMA (European Medicines Agency), Inaqovi - Product Information Sheet, 2023."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105228_bib26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105228_bib27","unstructured":"FDA (U. S. Food Drug Administration), Dacogen Report, 2010."},{"key":"10.1016\/j.critrevonc.2026.105228_bib28","unstructured":"FDA (U. S. Food Drug Administration), Venetoclax Report, 2022a."},{"key":"10.1016\/j.critrevonc.2026.105228_bib29","unstructured":"FDA (U. S. Food Drug Administration), Vidaza Report, 2022b."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105228_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000549","article-title":"Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed\/Refractory Advanced Myeloid Malignancies","volume":"5","author":"Feld","year":"2021","journal-title":"HemaSphere"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105228_bib31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ajh.27564","article-title":"Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax\u2009+\u2009Hypomethylating Agent","volume":"100","author":"Gangat","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105228_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262210818","article-title":"Molecular and Clinical Insights into TP53-Mutated MDS and AML","volume":"26","author":"Georgantzinos","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105228_bib33","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1016\/j.clml.2023.02.002","article-title":"Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting","volume":"23","author":"Gershon","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105228_bib34","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/s41375-023-01876-2","article-title":"In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts","volume":"37","author":"Greve","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105228_bib35","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41375-020-1003-x","article-title":"Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network","volume":"35","author":"Gu","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105228_bib36","article-title":"A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML","volume":"5","author":"Guo","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105228_bib37","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1038\/s41375-025-02780-7","article-title":"Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial","volume":"39","author":"Hund","year":"2025","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105228_bib38","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/cas.15663","article-title":"Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment","volume":"114","author":"Ikezoe","year":"2023","journal-title":"Cancer Sci."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105228_bib39","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1182\/blood-2022-165491","article-title":"Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy","volume":"140","author":"Ilyas","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105228_bib40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.bcp.2014.03.008","article-title":"Constitutive activation of the ATM\/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines","volume":"89","author":"Imanishi","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105228_bib41","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1002\/cncr.25247","article-title":"Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy","volume":"116","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"issue":"15_","key":"10.1016\/j.critrevonc.2026.105228_bib42","article-title":"Outcomes in AML patients receiving HMA + venetoclax combination with prior HMA exposure","volume":"39","author":"Jonathan","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105228_bib43","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","article-title":"Cellular differentiation, cytidine analogs and DNA methylation","volume":"20","author":"Jones","year":"1980","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105228_bib45","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20050821","article-title":"Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection","volume":"202","author":"Kolumam","year":"2005","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11010253","article-title":"Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives","volume":"11","author":"Leotta","year":"2022","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105228_bib47","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.molcel.2021.01.038","article-title":"DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells","volume":"81","author":"Loo Yau","year":"2021","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10767","article-title":"Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents","volume":"7","author":"Merlevede","year":"2016","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105228_bib49","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1182\/bloodadvances.2023011914","article-title":"Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials","volume":"8","author":"Montesinos","year":"2024","journal-title":"Blood Adv."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105228_bib50","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1182\/bloodadvances.2025016399","article-title":"Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1 -mutated AML","volume":"9","author":"Montesinos","year":"2025","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","article-title":"Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2\/3 study","volume":"35","author":"Montesinos","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib52","article-title":"Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics","volume":"11","author":"Morita","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15006-4","article-title":"Two distinct modes of DNMT1 recruitment ensure stable maintenance DNA methylation","volume":"11","author":"Nishiyama","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105228_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-06810-7","article-title":"Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia","volume":"15","author":"Nwosu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105228_bib55","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1158\/0008-5472.CAN-19-1696","article-title":"Activation of a Subset of Evolutionarily Young Transposable Elements and Innate Immunity Are Linked to Clinical Responses to 5-Azacytidine","volume":"80","author":"Ohtani","year":"2020","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010120","article-title":"Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness","volume":"12","author":"Palmieri","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105228_bib57","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105228_bib58","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105228_bib59","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable Residual Disease Response and Prognosis in Treatment-Na\u00efve Acute Myeloid Leukemia With Venetoclax and Azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105228_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023372","article-title":"Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome","volume":"6","author":"Qin","year":"2011","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105228_bib61","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105228_bib62","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26731","article-title":"Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes","volume":"97","author":"Rivera","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105228_bib63","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact","volume":"20","author":"Rizos","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105228_bib64","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/s41375-024-02211-z","article-title":"Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity","volume":"38","author":"Schwede","year":"2024","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105228_bib65","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3324\/haematol.2018.207118","article-title":"A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure","volume":"104","author":"S\u00e9bert","year":"2019","journal-title":"Haematologica"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105228_bib66","article-title":"Reconsidering the Significance of Blast Cut-Offs in Differentiating between MDS and AML Biology","volume":"142","author":"Shang","year":"2023","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105228_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164019","article-title":"A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data","volume":"15","author":"Sharplin","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105228_bib68","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/sj.leu.2403274","article-title":"Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia","volume":"18","author":"Shih","year":"2004","journal-title":"Leukemia"},{"issue":"7488","key":"10.1016\/j.critrevonc.2026.105228_bib69","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105228_bib70","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105228_bib71","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.3390\/ijms26115083","article-title":"Acquired Resistance to Decitabine Associated with the Deoxycytidine Kinase A180P Mutation: Implications for the Order of Hypomethylating Agents in Myeloid Malignancies Treatment","volume":"26","author":"Simonicova","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib72","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-025-01764-2","article-title":"Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens","volume":"25","author":"Soleimani Samarkhazan","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105228_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/cells11162589","article-title":"How Azanucleosides Affect Myeloid Cell Fate","volume":"11","author":"Stein","year":"2022","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105228_bib74","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105228_bib75","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105228_bib76","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/jha2.527","article-title":"Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy","volume":"3","author":"Symeonidou","year":"2022","journal-title":"eJHaem"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105228_bib77","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/leu.2013.165","article-title":"Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML","volume":"27","author":"Takahashi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2026.105228_bib78","unstructured":"TGA (Australian Therapeutic Goods Administration), Australian Public Assessment Report for azacitidine, 2013."},{"key":"10.1016\/j.critrevonc.2026.105228_bib79","unstructured":"TGA (Australian Therapeutic Goods Administration), AUSTRALIAN PRODUCT INFORMATION \u2013 INQOVI\u00ae 35\/100 (DECITABINE AND CEDAZURIDINE) TABLETS, 2021."},{"key":"10.1016\/j.critrevonc.2026.105228_bib80","unstructured":"TGA (Australian Therapeutic Goods Administration), AUSTRALIAN PRODUCT INFORMATION VENCLEXTA\u00ae (VENETOCLAX) FILM-COATED TABLETS, 2022."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-59796-x","article-title":"Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs","volume":"16","author":"Thoms","year":"2025","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105228_bib82","doi-asserted-by":"crossref","first-page":"28812","DOI":"10.18632\/oncotarget.15807","article-title":"Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive\/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease","volume":"8","author":"Tobiasson","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105228_bib83","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","article-title":"Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells","volume":"21","author":"Tsai","year":"2012","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105228_bib84","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.celrep.2017.06.067","article-title":"Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes","volume":"20","author":"Unnikrishnan","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2026.105228_bib85","series-title":"Acute Myeloid Leukemia","author":"Vakiti","year":"2025"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib86","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cyto.b.22158","article-title":"Flow cytometry of <scp>DNMT1<\/scp> as a biomarker of hypomethylating therapies","volume":"106","author":"Woost","year":"2024","journal-title":"Cytom. Part B Clin. Cytom."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105228_bib87","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.leukres.2014.08.016","article-title":"The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome","volume":"39","author":"Wu","year":"2015","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105228_bib88","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-016-0233-2","article-title":"Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials","volume":"8","author":"Yun","year":"2016","journal-title":"Clin. Epigenetics"},{"issue":"36","key":"10.1016\/j.critrevonc.2026.105228_bib89","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.2217\/fon-2021-0936","article-title":"Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?","volume":"17","author":"Zeidan","year":"2021","journal-title":"Future Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105228_bib90","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/bloodadvances.2020001779","article-title":"Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States","volume":"4","author":"Zeidan","year":"2020","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105228_bib91","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1007\/s00277-024-06117-9","article-title":"Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies","volume":"103","author":"Zha","year":"2024","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105228_bib92","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjh.16228","article-title":"Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML","volume":"188","author":"Zhao","year":"2020","journal-title":"Br. J. Haematol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:18:31Z","timestamp":1777605511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":92,"alternative-id":["S1040842826001150"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105228","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond initial response: Acquired resistance to hypomethylating agents in myeloid malignancies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105228","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105228"}}